GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Price-to-Owner-Earnings

Redx Pharma (LSE:REDX) Price-to-Owner-Earnings : (As of Jun. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Price-to-Owner-Earnings?

As of today (2024-06-14), Redx Pharma's share price is £0.15. Redx Pharma does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Redx Pharma's Price-to-Owner-Earnings or its related term are showing as below:

During the past 12 years, the highest Price-to-Owner-Earnings of Redx Pharma was 3.90. The lowest was 0.48. And the median was 1.59.


LSE:REDX's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.65
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-14), Redx Pharma's share price is £0.15. Redx Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.10. Therefore, Redx Pharma's PE Ratio for today is At Loss.

As of today (2024-06-14), Redx Pharma's share price is £0.15. Redx Pharma's EPS without NRI for the trailing twelve months (TTM) ended in was £-0.10. Therefore, Redx Pharma's PE Ratio without NRI for today is At Loss.

During the past 12 years, Redx Pharma's highest PE Ratio without NRI was 3.08. The lowest was 0.00. And the median was 1.25.


Redx Pharma Price-to-Owner-Earnings Historical Data

The historical data trend for Redx Pharma's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Price-to-Owner-Earnings Chart

Redx Pharma Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Redx Pharma Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Redx Pharma's Price-to-Owner-Earnings

For the Biotechnology subindustry, Redx Pharma's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redx Pharma's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Redx Pharma's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Redx Pharma's Price-to-Owner-Earnings falls into.



Redx Pharma Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Redx Pharma's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.15/-0.12
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Redx Pharma  (LSE:REDX) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Redx Pharma Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Redx Pharma's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Redx Pharma (LSE:REDX) Business Description

Traded in Other Exchanges
N/A
Address
Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG
Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines